Rhythm Pharmaceuticals Inc. reported pivotal Phase III results on 7 Aug. in two indications for setmelanotide, its lead drug candidate for the treatment of rare genetic obesity disorders, which it will use to complete a rolling new drug application (NDA) submission to the US Food and Drug Administration by the fourth quarter of 2019 or first quarter of 2020.
Setmelanotide is a melanocortin-4 receptor (MC4R) agonist designed to activate the MC4R pathway, which plays a key role in the...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)